Abstract
Recent studies show that activation of p38 mitogen-activated protein kinase (MAPK) results in cancer cell apoptosis initiated by retinoids, cisplatin and other chemotherapeutic agents. The observation that divergent therapies act through a common signal transduction pathway raises the possibility of developing new anti-cancer agents that lack the side-effects caused by events upstream of p38 MAPK. Here, we review p38-MAPK-mediated tumor cell apoptosis and implications for cancer therapeutics.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Apoptosis
-
Cisplatin / pharmacology
-
Drug Design
-
Enzyme Activation
-
Humans
-
MAP Kinase Signaling System / drug effects
-
Mitogen-Activated Protein Kinases / antagonists & inhibitors*
-
Mitogen-Activated Protein Kinases / metabolism
-
Neoplasms / drug therapy*
-
Neoplasms / enzymology
-
Retinoids / pharmacology
-
p38 Mitogen-Activated Protein Kinases
Substances
-
Antineoplastic Agents
-
Retinoids
-
Mitogen-Activated Protein Kinases
-
p38 Mitogen-Activated Protein Kinases
-
Cisplatin